Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR

IMPORTANCE: Patients with psoriasis enrolled in clinical trials of biologics may not be representative of the real-world population. There is evidence that patients ineligible for such trials have a greater risk of serious adverse events (SAEs), but the effect on drug discontinuation and effectivene...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :JAMA Dermatol
Главные авторы: Mason, Kayleigh J., Barker, Jonathan N. W. N., Smith, Catherine H., Hampton, Philip J., Lunt, Mark, McElhone, Kathleen, Warren, Richard B., Yiu, Zenas Z. N., Griffiths, Christopher E. M., Burden, A. David
Формат: Artigo
Язык:Inglês
Опубликовано: American Medical Association 2018
Предметы:
Original Investigation
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5876819/
https://ncbi.nlm.nih.gov/pubmed/29590279
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamadermatol.2018.0183
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы